GLPwatch
Papers (10404)
Page 96 of 174, ranked by citation count.
- Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.
- Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.
- [Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases.
- Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.
- Weight Loss Therapies and Hypertension Benefits.
- Association between Symptoms of Depression and Generalised Anxiety Disorder Evaluated through PHQ-9 and GAD-7 and Anti-Obesity Treatment in Polish Adult Women.
- Semaglutide 2.4 mg long-term clinical outcomes in patients with obesity or overweight: a real-world retrospective cohort study in the United States (SCOPE 12 months).
- Liraglutide provides neuroprotection by regulating autophagy through the AMPK-FOXO3 signaling pathway in a spinal contusion injury rat model.
- Liver paraoxonase 3 expression and the effect of liraglutide treatment in a rat model of diabetes.
- GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice.
- Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy.
- Effect of the glucagon-like peptide-1 receptor agonists on diabetic peripheral neuropathy: A meta-analysis.
- Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment.
- Intranasal Exendin-4 modifies necroptosis-mediated innate immune response to combat septic encephalopathy in rats: Role of mTORC1 in immunogenic and tolerogenic cell demise.
- Microcosmic mechanism of dication for inhibiting acylation of acidic Peptide.
- Efficacy and safety of once-weekly exenatide after switching from twice-daily exenatide in patients with type 2 diabetes.
- Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.
- Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats.
- Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
- Glycaemic control with liraglutide: the phase 3 trial programme.
- Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.
- Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance.
- Targeting microglial GLP1R in epilepsy: A novel approach to modulate neuroinflammation and neuronal apoptosis.
- Preventing progression from gestational diabetes mellitus to diabetes: A thought-filled review.
- Influence of Dulaglutide on Serum Biomarkers of Atherosclerotic Plaque Instability: An Interventional Analysis of Cytokine Profiles in Diabetic Subjects-A Pilot Study.
- Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis.
- Effect of lixisenatide on liquid gastric emptying in type 2 diabetes - Implications for the use of GLP-1 receptor agonists before procedures.
- Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?
- Activation of the renal GLP-1R leads to expression of <i>Ren1</i> in the renal vascular tree.
- A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada.
- Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers.
- Structure-Activity Relationships and Pharmacokinetics of <sup>111</sup>In-Labeled Glucagon-like Peptide-1 Receptor-Targeting Exendin-4 Derivatives Conjugated with Albumin Binder Moieties.
- Semaglutide Alleviates Ovarian Oxidative Stress and Autophagy via the PI3K/AKT/mTOR Pathway in Mice with Polycystic Ovary Syndrome.
- Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice.
- Cyclic AMP-mediated pleiotropic effects of glucagon-like peptide-1 receptor activation. Focus on "Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a".
- Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.
- Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real-world UK data: A clinical evaluation of a multi-ethnic population.
- SAD-A Promotes Glucose-Stimulated Insulin Secretion Through Phosphorylation and Inhibition of GDIα in Male Islet β Cells.
- Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
- Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy.
- The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes-A Scientometric Investigation and Visualization Study.
- Palatable food avoidance and acceptance learning with different stressors in female rats.
- A Rare Case of Dulaglutide-Associated Angioedema in a Male Patient.
- The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.
- Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.
- Weight Recidivism After Bariatric Surgery: A Narrative Review.
- A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
- Exendin-4 promotes proliferation of adipose-derived stem cells through PI3K/Akt-Wnt signaling pathways.
- Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.
- Liraglutide stimulates the β-catenin signaling cascade in mouse epididymal fat tissue.
- Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.
- A mouse model of weight gain after nicotine withdrawal.
- Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review.
- Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
- Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice.
- Exendin-4 exhibits a tumour suppressor effect in SKOVR-3 and OVACR-3 ovarian cancer cells lines by the activation of SIRT1 and inhibition of NF-κB.
- Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
- Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.
- Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
- Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death.